Sivik Global Healthcare LLC Reduces Position in Humana Inc. (NYSE:HUM)

Sivik Global Healthcare LLC decreased its position in Humana Inc. (NYSE:HUM) by 14.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 15,000 shares of the insurance provider’s stock after selling 2,500 shares during the period. Humana comprises approximately 2.9% of Sivik Global Healthcare LLC’s portfolio, making the stock its 12th biggest holding. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,867,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after acquiring an additional 119,760 shares during the period. Ameriprise Financial Inc. raised its position in Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares during the last quarter. Northern Trust Corp lifted its holdings in Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock worth $645,850,000 after buying an additional 64,245 shares during the period. Invesco Ltd. grew its position in shares of Humana by 1.4% in the 3rd quarter. Invesco Ltd. now owns 965,488 shares of the insurance provider’s stock worth $469,729,000 after buying an additional 13,670 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Humana by 39.3% during the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after buying an additional 192,546 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM traded down $1.06 during trading hours on Tuesday, reaching $302.09. The company had a trading volume of 1,565,451 shares, compared to its average volume of 1,990,495. The firm has a market cap of $36.40 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 1.79 and a beta of 0.45. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average price is $325.94 and its 200-day moving average price is $392.00. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.38 earnings per share. On average, analysts forecast that Humana Inc. will post 16.08 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.17%. Humana’s dividend payout ratio (DPR) is 22.04%.

Insider Buying and Selling at Humana

In related news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HUM. The Goldman Sachs Group cut their price target on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Oppenheimer cut their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Cantor Fitzgerald dropped their price target on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Bank of America reissued a “neutral” rating and set a $342.00 price objective (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Finally, Stephens dropped their target price on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.